AADI Earnings Prediction
The chart below shows how AADI performed 10 days before and after its earnings report, based on data from the past quarters. Typically, AADI sees a +5.30% change in stock price 10 days leading up to the earnings, and a +8.26% change 10 days following the report. On the earnings day itself, the stock moves by -2.69%. This data can give you a slight idea of what to expect for the next quarter's release.
AADI Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
6.18M
-0.37%
15.43%
Gross Margin
87.41%
-2.25%
-0.47%
Operating Margin
-252.21%
-19.97%
-30.81%
Net Margin
-236.01%
-18.55%
-30.92%
EPS
-0.54
-19.40%
-20.59%
No Data Available
AADI Earnings Analysis
Aadi Bioscience, Inc. Common Stock Corporation (AADI.O) Earnings Conference Call
Positive
Aadi Bioscience has achieved $51.1 million in sales of FYARRO since its launch in February 2022, indicating high demand and penetration across academic and community settings, with consistent addition of new ordering accounts.
FYARRO product sales were $6.2 million in the second quarter, in line with the prior year period and up 15% over Q1, with a growth observed across all segments, including large accounts.
More than 200 accounts have ordered FYARRO since its launch, showcasing a consistent addition of new accounts ordering the product.
Aadi Bioscience's responsible capital management has resulted in a healthy balance sheet, with $78.6 million in cash, cash equivalents, and short-term investments. This will fund operations into Q4 2025 based on current plans.
Research and development expenses for the quarter were $13.1 million, mainly related to the progress of the ongoing PRECISION1 trial and programs in endometrial cancer and NET.
Selling, general and administrative expenses decreased to $7.9 million compared to the previous year, driven by reduced commercial, marketing, personnel expenses, and legal expenses.
Aadi Bioscience is making significant progress in its clinical development plans, targeting sizable markets in TSC1 and TSC2 inactivating alterations as well as other mTOR-driven cancers.
The anticipated two-thirds interim analysis from PRECISION1 is expected later this quarter, with plans to share data with the FDA if appropriate, expecting full results by 2025.
Initial data from the EEC and NET trials are planned to be provided by the end of the year, with potential FDA filing based on data from PRECISION1 in 2025.
Negative
- Net loss for the second quarter was $14.6 million, showing a significant increase from the previous year.
- Research and development expenses remained high at $13.1 million, indicating ongoing financial burdens.
- Despite responsible capital management, the cash runway is anticipated to extend only until Q4 2025, highlighting potential financial constraints in the near future.
AADI FAQs
How does AADI typically perform around its earnings report dates?
Is Aadi Bioscience, Inc. (AADI) Q2 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
AADI Earning Call Sentiment
Aadi Bioscience, Inc. (AADI) Q2 2024 Earnings Call Transcript
1.0x
00:00
00:00
AADI.O
4.76%Positive
The earnings call presents a mixed picture: stable financial performance with a decrease in net loss and increased FYARRO sales, but ongoing financial challenges and risks from clinical trials. The Q&A section highlights management's uncertainty in key areas, like TSC1 and 2 expectations, and vague responses on sales potential, which may concern investors. Despite positive cash flow and a promising market opportunity, uncertainties in trial outcomes and market adoption, along with lack of guidance, suggest a neutral short-term stock price movement.